Journal of Clinical Psychiatry

Subject Index to Volume 46: January 1985 Through December 1985

Adolescents
Developmental manifestations in a boy with prepubertal bipolar disorder. Oct, 441-443
Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: Case report. March, 100-103

Affective Disorders: See also Mania; Depression
A proposed clinical approach to chronic and "resistant" depressions: Evaluation and treatment. Oct, Sec 2, 32-36
Alternative therapies for bipolar disorder. Aug, 309-316
Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects. Jan, 22-25
Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: Case report. Nov, 487-488
Developmental considerations in the concept of affective illness. Oct, Sec 2, 46-53
Euthyroid hyperthyroxinemia and rapid cycling affective disorder: Case report. Feb, 61-63
Family history of suicide in affective disorder patients. Aug, 317-319
Introduction: Update on the clinical management of affective illness. Oct, Sec 2, 3-5
The dexamethasone suppression test and unipolar/bipolar distinctions. Nov, 461-465
Transition from bipolar affective disorder to intermittent Cushing's syndrome: Case report. May, 194-196
Use of biologic markers in a general hospital affective disorders program. June, 217-221

Agitation
Agitation observed during treatment with newer hypnotic drugs. July, 280-283
Droperidol and haloperidol in the treatment of acute agitation (letter with reply). Sept, 407

Agoraphobia
Depression, agoraphobia, and the DST (letter). Nov, 503-504

Agranulocytosis
Agranulocytosis in the course of phenothiazine therapy: Case reports. Aug, 341-343

Akathisia
Three cases of akathisia and "acting out." Sept, 395-397

Alcohol and Alcoholism
Disulfiram hepatotoxicity: Case report. Feb, 67-68
Halazepam in the management of acute alcohol withdrawal syndrome. May, 172-174
Prevalence of anxiety disorders among alcoholics. Jan, 3-5

Alprazolam
Alprazolam in severe depression (letter). Jan, 34
Alprazolam-induced manic switch (letter). Sept, 406-407
Alprazolam overdose: Clinical findings and serum concentrations in two cases. June, 247-248
Alprazolam withdrawal delirium unresponsive to diazepam: Case report. Aug, 344-345
Refractory migraine headache controlled with alprazolam: Case report. Nov, 494-495
Treatment of pavor nocturnus with alprazolam (letter). Nov, 504

Alzheimer's Disease
Lithium neurotoxicity in patients with degenerative brain disease (letter with reply). Aug, 354
Sleep apnea in Alzheimer's dementia: Correlation with mental deterioration. July, 257-261

Amitriptyline
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Sept, 369-372
A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. Jan, 6-8
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. March, Sec 2, 32-37
Amitriptyline and contact lenses (letter). May, 199
Plasma levels of amitriptyline: Effect of age and sex. July, 276-277

Amnesia
Anterograde amnesia with oral lorazepam. April, 137-138

Amoxapine
Amoxapine overdose (letter). Dec, 545
Treatment of depression in inpatients: A controlled comparison of the onset of action of amoxapine and maprotiline. Dec, 521-524

AMP
AMP: A new form of marijuana. Nov, 498-499

Androgens, Synthetic
A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. Jan, 6-8
Androgen-induced hypomania (letter). Aug, 354-355

Anorexia
Anorexia nervosa in a 45-year-old man (letter with reply). Aug, 355
Concurrence of Turner's syndrome, anorexia nervosa, and mood disorders: Case report. July, 296-297
Prevalence of anorexia nervosa and bulimia among young diabetic women. March, 88-89

Antidepressants: See also specific drugs
A proposed clinical approach to chronic and "resistant" depressions: Evaluation and treatment. Oct, Sec 2, 32-36
Antidepressants and myoclonus: Case report. July, 284-287
Clinical guidelines for the use of antidepressant drugs in geriatric patients. Oct, Sec 2, 38-44
Combination drug therapy in depression (editorial). June, 205
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. June, 206-209
Depression after minor closed head injury: Role of dexamethasone suppression test and antidepressants. Aug, 335-338
Development of new treatments for depression. March, Sec 2, 3-6
Patterns of attrition for psychosocial and pharmacologic treatments of depression. Sept, 361-366
The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. Feb, 58-60
The new generation antidepressants: Promising innovations or disappointments? Oct, Sec 2, 25-30
Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Oct, Sec 2, 6-22
Trimipramine and maprotiline: Antidepressant, anxiolytic, and cardiotoxic comparison. May, 166-171

Anxiety: See also Panic Attacks; Panic Disorder
Lactate infusion in anxiety research: Its evolution and practice. May, 158-165
Panic anxiety (letter). Oct, 455
Prevalence of anxiety disorders among alcoholics. Jan, 3-5
Protocols for the use of psychoactive drugs—Part IV: Protocol for the treatment of anxiety disorders. April, 128-132
Pseudocholinesterase and trait anxiety in premenstrual tension syndrome. April, 139-140

Attention Deficit Disorder
The use of imipramine in Tourette's syndrome and attention deficit disorder: Case report. Aug, 348-349

Autoimmune Deficiency Syndrome
New psychopathologic findings in AIDS: Case report. June, 240-241

Biologic Markers: See also specific tests
Thyroid indices in panic disorder. Oct, 432-433
Thyroxine binding and TSH in recurrent depressive episodes. July, 267-272
Use of biologic markers in a general hospital affective disorders program. June, 217-221

Borderline Personality Disorder
Borderline: An adjective in search of a noun. Feb, 41-48
Electroencephalographic abnormalities in borderline patients (letter). June, 251

Bromide
Elevated serum bromide in patients taking lithium carbonate. Jan, 9-10

Bromocriptine
Concurrent use of bromocriptine and fluphenazine (letter). Oct, 455

Bulimia
Prevalence of anorexia nervosa and bulimia among young diabetic women. March, 88-89

Bupropion
Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects. Jan, 22-25

Calcium Channel Blockers
Calcium channel blockers in the treatment of panic disorder (letter). Dec, 546

Capgras Syndrome
A case of Capgras delusion presenting as a postpartum psychosis. June, 242-243

Carbamazepine
Carbamazepine and idiopathic thrombocytopenia (letter). May, 199
Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: Case report. Nov, 487-488
Carbamazepine in mixed frontal lobe and psychiatric disorders. Sept, 393-394
Carbamazepine treatment of a patient with Kluver-Bucy syndrome. Nov, 496-497
The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. Feb, 58-60

Cardiotoxicity: See also Side Effects
Dose-related physostigmine-induced ventricular arrhythmia: Case report. Oct, 446-447
Effect of fluoxetine on the electrocardiogram. March, Sec 2, 42-44
Monoamine oxidase inhibitors for depressed cardiac patients (letter). Dec, 545-546
Noninvasive assessment of electroconvulsive-induced changes in cardiac function. Nov, 479-482
Psychotropic drugs and long QT syndromes: Case reports. July, 290-291
Trimipramine and maprotiline: Antidepressant, anxiolytic, and cardiotoxic comparison. May, 166-171
Catatonia
Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: Case report. July, 288-289
Children
Molindone hydrochloride treatment of hospitalized children with conduct disorder. Aug, Sec 2, 20-25
The dexamethasone suppression test in prepubertal depressed children. Dec, 511-513
The use of ECT in children: Case report. March, 98-99
Chlorimipramine
Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: Case report. March, 100-103
Chlorpromazine
Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. Feb, 52-54
Cholecystokinin
Is cholecystokinin therapeutic in chronic schizophrenia? Nov, 485-486
Chromosomal Abnormalities
Homicidality in a woman with a 47,XXX karyotype. Aug, 346-347
Clonazepam
Use of clonazepam in two cases of acute mania. Jan, 29-30
Clonidine
Effects of clonidine in narcolepsy. Dec, 528-531
Clorazepate
Lack of amnestic effects of clorazepate on geriatric recall. Dec, 518-520
CME Tests
CME tests. May, Sec 2, 41-43
Cognitive Dysfunction
Screening for cognitive toxicity of anticholinergic drugs. Aug, 323-326
Compliance
Drugs and the quality of life: The patient's point of view. May, Sec 2, 29-35
Conduct Disorder
Molindone hydrochloride treatment of hospitalized children with conduct disorder. Aug, Sec 2, 20-25
Conversion Disorder
Methylphenidate in diagnosing conversion symptoms (letter). March, 110-111
Dantrolene
Resolution of neuroleptic malignant syndrome with dantrolene sodium: Case report. June, 244-246
Delirium
Partial resolution of ranitidine-associated delirium with physostigmine: Case report. Sept, 400-401
Dementia
Concurrent depression and dementia: Implications for diagnosis and treatment. Sept, 389-392
Revised ischemic score for diagnosing multi-infarct dementia. Dec, 514-517
Depression: See also Affective Disorders; Antidepressants
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Sept, 369-372
A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. March, 90-94
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. March, Sec 2, 26-31
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. March, Sec 2, 32-37
A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. March, 84-87
A proposed clinical approach to chronic and "resistant" depressions: Evaluation and treatment. Oct, Sec 2, 32-36
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. March, Sec 2, 53-58
Age, medical illness, and the DST in depressed general hospital inpatients. March, 95-97
Alprazolam in severe depression (letter). Jan, 34
Clinical significance, evaluation, and management of secondary depression in schizophrenia. Nov, Sec 2, 26-32
Combination drug therapy in depression (editorial). June, 205
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. June, 206-209
Concurrent depression and dementia: Implications for diagnosis and treatment. Sept, 389-392
Depression after minor closed head injury: Role of dexamethasone suppression test and antidepressants. Aug, 335-338
Depression and suicidality in eating disorders. April, 118-124
Depression, agoraphobia, and the DST (letter). Nov, 503-504
Depressive symptoms in acute schizophrenic hospitalized patients. Nov, 483-484
Development of new treatments for depression. March, Sec 2, 3-6
Diagnosis of secondary depression in schizophrenia. Nov, Sec 2, 4-8
Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. March, Sec 2, 20-25
Frequency and differential diagnosis of depressive syndromes in schizophrenia. Nov, Sec 2, 9-13
Introduction: Secondary depression in schizophrenia. Nov, Sec 2, 3
Maprotiline in pain-depression. June, 226-228
Methylphenidate in mild depression: A double-blind controlled trial. Dec, 525-527
Patterns of attrition for psychosocial and pharmacologic treatments of depression. Sept, 361-366
The dexamethasone suppression test in prepubertal depressed children. Dec, 511-513
The use of ECT in children: Case report. March, 98-99
Thyroxine binding and TSH in recurrent depressive episodes. July, 267-272
Treatment of depression in outpatients: A controlled comparison of the onset of action of amoxapine and maprotiline. Dec, 521-524
Tricyclic-resistant depression: Treatment resistance or inadequate treatment? Oct, 412-417
Trimipramine in physical illness with depression. Feb, Sec 2, 4-8
Use of ECT in a depressed hypothyroid patient. Feb, 64-66
Depression, Delusional
Dexamethasone suppression test results in delusional versus nondelusional depression: Preliminary evidence of distinct clinical entities. May, 188-190
Rapid improvement of delusional depression following drug-induced seizures: Case report. April, 146-147
Developmental Issues
Developmental considerations in the concept of affective illness. Oct, Sec 2, 46-53
Developmental manifestations in a boy with prepubertal bipolar disorder. Oct, 441-443
Dexamethasone Suppression Test
Age, medical illness, and the DST in depressed general hospital inpatients. March, 95-97
Depression after minor closed head injury: Role of dexamethasone suppression test and antidepressants. Aug, 335-338
Depression, agoraphobia, and the DST (letter). Nov, 503-504
Dexamethasone suppression test: A review of contemporary confusion. Feb, Sec 2, 13-24
Dexamethasone suppression test results in delusional versus nondelusional depression: Preliminary evidence of distinct clinical entities. May, 188-190
Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
Does the dexamethasone suppression test have clinical utility in psychiatry? Feb, Sec 2, 25-29
Effect of estrogens on the DST (letter). Nov, 505
The dexamethasone suppression test and unipolar/bipolar distinctions. Nov, 461-465
The dexamethasone suppression test in prepubertal depressed children. Dec, 511-513
The DST: A specialized but important clinical tool (letter). June, 251
The validity of the DST (letter). March, 110
Diagnostic Techniques: See also Rating Scales
The discriminate validity of the Psychiatric Diagnostic Interview. Aug, 320-322
Diazepam
Increased sensitivity of the elderly to the central depressant effects of diazepam. May, 185-187
Six-week trial with diazepam: Some clinical observations. Nov, 470-474
Diltiazem
A possible interaction between lithium and diltiazem: Case report. Dec, 540-541
Disability
Disability and welfare—Who wants it? July, 273-275
Disulfiram
Disulfiram hepatotoxicity: Case report. Feb, 67-68
Dosage Studies/Prediction
Accuracy and safety of a priori lithium loading. Feb, 49-51
Antipsychotic drug side effects: Their relationship to dose. May, Sec 2, 16-21
Comparison of two dosage regimens of fluoxetine in major depression. March, Sec 2, 38-41
Relationship between patient variables and lithium dosage requirements. April, 133-136
Tear lithium concentration (letter with reply). April, 150
Doxepin
A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. March, 90-94
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. March, Sec 2, 20-25
Droperidol
Droperidol and haloperidol in the treatment of acute agitation (letter with reply). Sept, 407
Drug Abuse: See also specific drugs
AMP: A new form of marijuana. Nov, 498-499
Drug abuse among state hospital psychiatric inpatients with particular reference to PCP. Aug, 339-340
Drug Dependence/Withdrawal
Alprazolam withdrawal delirium unresponsive to diazepam: Case report. Aug, 344-345
Drug Interactions
A possible interaction between lithium and diltiazem: Case report. Dec, 540-541
Eating Disorders: See also Anorexia; Bulimia
Depression and suicidality in eating disorders. April, 118-124
Electroconvulsive Therapy
Bilateral sinusoidal ECT following poor response to five unilateral brief-pulse ECTs. Oct, 430-431
ECT: An assessment of mental health professionals' knowledge and attitudes. July, 262-266
ECT in the presence of increased intracranial pressure and respiratory failure: Case report. Nov, 489-491
Electroconvulsive therapy: A survey of use in the private psychiatric hospital. April, 125-127
Noninvasive assessment of electroconvulsive-induced changes in cardiac function. Nov, 479-482
The use of ECT in children: Case report. March, 98-99
Use of ECT in a depressed hypothyroid patient. Feb, 64-66
Electroencephalography
Electroencephalographic abnormalities in borderline patients (letter). June, 251
Encephalopathy
Depression in Binswanger's encephalopathy responsive to tranylcypromine: Case report. Feb, 69-70
Enuresis
Maprotiline in nocturnal enuresis (letter). Dec, 546

Epidemiology
Similar distribution of schizophrenia and multiple sclerosis (letter). Feb, 73
Suicide in schizophrenia: The Iowa record linkage study. Nov, Sec 2, 14-17
Suicide pacts: International comparisons. Jan, 11-15
Erotomania
A case of homosexual erotomania. Oct, 448-449
Estrogen
Effect of estrogens on the DST (letter). Nov, 505
Family Studies
Family history of suicide in affective disorder patients. Aug, 317-319
Fluoxetine
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Sept, 369-372
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. March, Sec 2, 26-31
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. March, Sec 2, 32-37
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. March, Sec 2, 53-58
Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses. March, Sec 2, 45-52
Comparison of two dosage regimens of fluoxetine in major depression. March, Sec 2, 38-41
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. March, Sec 2, 20-25
Effect of fluoxetine on the electrocardiogram. March, Sec 2, 42-44
Fluoxetine: Clinical pharmacology and physiologic disposition. March, Sec 2, 14-19
The pharmacologic profile of fluoxetine. March, Sec 2, 7-13
The side effect profile and safety of fluoxetine. March, Sec 2, 59-67
Fluphenazine
Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: Case report. July, 288-289
Concurrent use of bromocriptine and fluphenazine (letter). Oct, 455
Fluvoxamine
A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. March, 84-87
Gamma-Hydroxybutyrate
The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. June, 222-225
Geriatric Patients
Acute response to methylphenidate as a predictor of outcome of treatment with TCAs in the elderly. Nov, 466-469
Antipsychotic medication and the elderly. May, Sec 2, 36-40
Clinical experience with molindone hydrochloride in geriatric patients. Aug, Sec 2, 26-29
Clinical guidelines for the use of antidepressant drugs in geriatric patients. Oct, Sec 2, 38-44
Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. March, Sec 2, 20-25
Increased sensitivity of the elderly to the central depressant effects of diazepam. May, 185-187
Lack of amnestic effects of clorazepate on geriatric recall. Dec, 518-520
Predicting the results of routine laboratory tests in elderly psychiatric patients admitted to hospital. Dec, 532-534
Sleeping pills for the elderly: Are they ever justified? Feb, Sec 2, 9-12
The prevalence of tardive dyskinesia in geropsychiatric outpatients. Feb, 55-57
Halazepam
Halazepam in the management of acute alcohol withdrawal syndrome. May, 172-174
Hallucinations
Auditory hallucinosis and atypical tic disorder: Case reports. Sept, 398-399
Haloperidol
Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Aug, Sec 2, 15-19
Droperidol and haloperidol in the treatment of acute agitation (letter with reply). Sept, 407
Elimination half-life and bioavailability of haloperidol in schizophrenic patients. Jan, 20-21
Molindone and haloperidol in tardive dyskinesia. Aug, Sec 2, 4-7
Health Care Delivery
Gresham's law in psychiatric illness (editorial). Aug, 308
Homicide
Homicidality in a woman with a 47,XXX karyotype. Aug, 346-347
Homosexuality
A case of homosexual erotomania. Oct, 448-449
Hyperphagia
Hyperphagia in premenstrual tension syndrome. Oct, 436-438
Hypnoanalgesia
Biochemical correlates of hypnoanalgesia in arthritic pain patients. June, 235-238
Hyponatremia
Polydipsia and chronic hyponatremia in schizophrenic inpatients. May, 179-181
Imipramine
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. March, Sec 2, 26-31
A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. March, 84-87
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. March, Sec 2, 53-58
The use of imipramine in Tourette's syndrome and attention deficit disorder: Case report. Aug, 348-349
Industrial Toxins
Schizophreniform psychosis associated with chronic industrial toluene exposure: Case report. Aug, 350-351
Informed Consent
Tardive dyskinesia, impaired recall, and informed consent. Oct, 434-435
Insulin
Suicide attempt by insulin overdose (letter). Jan, 34
Ketoacidosis
Diabetic ketoacidosis associated with lithium: Case report. Nov, 492-493
Kluver-Bucy Syndrome
Carbamazepine treatment of a patient with Kluver-Bucy syndrome. Nov, 496-497
L-Phenylalanine
L-Phenylalanine (letter). Aug, 355
Laboratory Analyses: See also Plasma Levels; specific tests
Predicting the results of routine laboratory tests in elderly psychiatric patients admitted to hospital. Dec, 532-534
Lactate Infusion
Lactate infusion in anxiety research: Its evolution and practice. May, 158-165
Lithium
A possible interaction between lithium and diltiazem: Case report. Dec, 540-541
Accuracy and safety of a priori lithium loading. Feb, 49-51
Brain glycine levels following lithium toxicity: Case report. June, 239
Diabetic ketoacidosis associated with lithium: Case report. Nov, 492-493
Downbeat nystagmus as a side effect of lithium carbonate: Case report. July, 292-293
Elevated serum bromide in patients taking lithium carbonate. Jan, 9-10
Funeral mania and lithium prophylaxis (letter). March, 111
Lithium carbonate and the "cycloid spectrum" (letter). Nov, 504-505
Lithium Information Center: The Lithium Library revisited. Aug, 327-331
Lithium neurotoxicity in patients with degenerative brain disease (letter with reply). Aug, 354
Lithium treatment of central pain (letter). Oct, 453-454
Lithium-induced neurotoxicity and irreversible brain damage: A possible mechanism and antidote (letter). July, 300
Lithium-responsive schizophrenia: Case report. April, 141-142
Non-lithium-induced renal failure with secondary lithium toxicity: Case reports. Jan, 26-28
Ordinary conditions for indefinite continuation of lithium therapy (letter). Nov, 505
Relationship between patient variables and lithium dosage requirements. April, 133-136
Tear lithium concentration (letter with reply). April, 150
The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. Feb, 58-60
Theophylline-lithium interaction. July, 278-279
Treatment-emergent incontinence with lithium. Oct, 444-445
Water intoxication associated with nephrogenic diabetes insipidus secondary to lithium: Case report. Sept, 402-403
Lorazepam
Anterograde amnesia with oral lorazepam. April, 137-138
Maintenance Treatment
Antipsychotic medication: Clinical guidelines for maintenance therapy. May, Sec 2, 6-15
Maintenance therapy and the natural course of schizophrenia. Nov, Sec 2, 18-21
Ordinary conditions for indefinite continuation of lithium therapy (letter). Nov, 505
Prodromal symptoms and prevention of relapse in schizophrenia. Nov, Sec 2, 22-25
Mania
A case of mania secondary to propafenone. March, 104-105
Alprazolam-induced manic switch (letter). Sept, 406-407
Funeral mania and lithium prophylaxis (letter). March, 111
Use of clonazepam in two cases of acute mania. Jan, 29-30
MAO Inhibitors
Combination drug therapy in depression (editorial). June, 205
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. June, 206-209
Monoamine oxidase inhibitors for depressed cardiac patients (letter). Dec, 545-546
Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Oct, Sec 2, 6-22
Maprotiline
Maprotiline in nocturnal enuresis (letter). Dec, 546
Maprotiline in pain-depression. June, 226-228
Tonic-clonic seizures with maprotiline (letter). Nov, 503
Treatment of depression in outpatients: A controlled comparison of the onset of action of amoxapine and maprotiline. Dec, 521-524
Trimipramine and maprotiline: Antidepressant, anxiolytic, and cardiotoxic comparison. May, 166-171
Medical Illness
Age, medical illness, and the DST in depressed general hospital inpatients. March, 95-97
Biochemical correlates of hypnoanalgesia in arthritic pain patients. June, 235-238
Carbamazepine in mixed frontal lobe and psychiatric disorders. Sept, 393-394
Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
ECT in the presence of increased intracranial pressure and respiratory failure: Case report. Nov, 489-491
Monoamine oxidase inhibitors for depressed cardiac patients (letter). Dec, 545-546
Prevalence of anorexia nervosa and bulimia among young diabetic women. March, 88-89
Similar distribution of schizophrenia and multiple sclerosis (letter). Feb, 73
Transition from bipolar affective disorder to intermittent Cushing's syndrome: Case report. May, 194-196
Trimipramine in physical illness with depression. Feb, Sec 2, 4-8
Melancholia
Treatment responses in primary and secondary melancholia: A preliminary report. Aug, 332-334

Memory
Tardive dyskinesia, impaired recall, and informed consent. Oct, 434-435
Meperidine
Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. Feb, 52-54
Mesterolone
A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. Jan, 6-8
Methylphenidate
Acute response to methylphenidate as a predictor of outcome of treatment with TCAs in the elderly. Nov, 466-469
Methylphenidate in diagnosing conversion symptoms (letter). March, 110-111
Methylphenidate in mild depression: A double-blind controlled trial. Dec, 525-527
Metrizamide
Metrizamide myelography risk factors: A pseudopsychiatric case presentation. Oct, 439-440
Migraine Headaches
Refractory migraine headache controlled with alprazolam: Case report. Nov, 494-495
Molindone
Clinical experience with molindone hydrochloride in geriatric patients. Aug, Sec 2, 26-29
Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Aug, Sec 2, 15-19
Molindone and haloperidol in tardive dyskinesia. Aug, Sec 2, 4-7
Molindone hydrochloride treatment of hospitalized children with conduct disorder. Aug, Sec 2, 20-25
Review of clinical and laboratory experiences with molindone hydrochloride. Aug, Sec 2, 30-33
Myoclonus
Antidepressants and myoclonus: Case report. July, 284-287
Narcolepsy
Effects of clonidine in narcolepsy. Dec, 528-531
Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: Case report. May, 191-193
The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. June, 222-225
Neuroleptic Malignant Syndrome
Resolution of neuroleptic malignant syndrome with dantrolene sodium: Case report. June, 244-246
Neuroleptics
Antipsychotic drug side effects: Their relationship to dose. May, Sec 2, 16-21
Antipsychotic medication: Clinical guidelines for maintenance therapy. May, Sec 2, 6-15
Antipsychotic medication and the elderly. May, Sec 2, 36-40
Antipsychotic or neuroleptic? (letter). Oct, 454-455
Blood levels of neuroleptics: State of the art. May, Sec 2, 22-28
Drugs and the quality of life: The patient's point of view. May, Sec 2, 29-35
Interpatient variations in antipsychotic therapy. May, Sec 2, 3-5
Introduction: Theoretical and clinical considerations affecting the selection of neuroleptic agents. Aug, Sec 2, 3
Neuroleptic drugs and their action on different neuronal pathways. April, Sec 2, 34-37
New antipsychotic agents and the future. April, Sec 2, 51-53
Pharmacology of antipsychotic drugs. April, Sec 2, 25-28
Pharmacology of neuroleptics in use in the United States. Aug, Sec 2, 8-14
Rapid tranquilization: The efficacy of oral concentrate. Nov, 475-478
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine. Oct, 428-429
Vulnerability to tardive dyskinesia. Sept, 367-368
Neurotransmitters
Neuroleptic drugs and their action on different neuronal pathways. April, Sec 2, 34-37
Nortriptyline
Nortriptyline pharmacokinetics and plasma levels: Implications for clinical practice. Oct, 418-424
Obsessive-Compulsive Disorder
Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: Case report. March, 100-103
Overdose
Alprazolam overdose: Clinical findings and serum concentrations in two cases. June, 247-248
Amoxapine overdose (letter). Dec, 545
Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: Case report. July, 288-289
Pain
Biochemical correlates of hypnoanalgesia in arthritic pain patients. June, 235-238
Lithium treatment of central pain (letter). Oct, 453-454
Maprotiline in pain-depression. June, 226-228
Prediction of response to treatment in chronic pain patients. Oct, 425-427
Panic Attacks: See also Anxiety; Panic Disorder
Combat-related flashbacks in posttraumatic stress disorder: Phenomenology and similarity to panic attacks. Sept, 379-382
Panic attacks and temporal lobe seizures associated with a right temporal lobe arteriovenous malformation: Case report. April, 143-145
Panic Disorder
Calcium channel blockers in the treatment of panic disorder (letter). Dec, 546
Panic anxiety (letter). Oct, 455
Panic disorder and PTSD (letter). Oct, 454
Thyroid indices in panic disorder. Oct, 432-433
Pharmacokinetics/Pharmacology
Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses. March, Sec 2, 45-52
Elimination half-life and bioavailability of haloperidol in schizophrenic patients. Jan, 20-21
Fluoxetine: Clinical pharmacology and physiologic disposition. March, Sec 2, 14-19
Pharmacology of antipsychotic drugs. April, Sec 2, 25-28
Pharmacology of neuroleptics in use in the United States. Aug, Sec 2, 8-14
The pharmacologic profile of fluoxetine. March, Sec 2, 7-13
Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Oct, Sec 2, 6-22
Phencyclidine
Drug abuse among state hospital psychiatric inpatients with particular reference to PCP. Aug, 339-340
Reserpine and phencyclidine-associated psychosis: Three case reports. Dec, 542-544
Phenothiazines
Agranulocytosis in the course of phenothiazine therapy: Case reports. Aug, 341-343
Phenylpropanolamine
Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: Case report. July, 288-289
Physostigmine
Dose-related physostigmine-induced ventricular arrhythmia: Case report. Oct, 446-447
Partial resolution of ranitidine-associated delirium with physostigmine: Case report. Sept, 400-401
Plasma levels
Blood levels of neuroleptics: State of the art. May, Sec 2, 22-28
Elevated serum bromide in patients taking lithium carbonate. Jan, 9-10
Nortriptyline pharmacokinetics and plasma levels: Implications for clinical practice. Oct, 418-424
Plasma levels of amitriptyline: Effect of age and sex. July, 276-277
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine. Oct, 428-429
Tricyclic antidepressant blood levels. Dec, 545
Polydipsia
Polydipsia and chronic hyponatremia in schizophrenic inpatients. May, 179-181
Posttraumatic Stress Syndrome
Combat-related flashbacks in posttraumatic stress disorder: Phenomenology and similarity to panic attacks. Sept, 379-382
Olfactory precipitants of flashbacks in posttraumatic stress disorder: Case reports. Sept, 383-384
Panic disorder and PTSD (letter). Oct, 454
Posttraumatic flashbacks, dream disturbances, and mental imagery. Sept, 374-378
Posttraumatic stress disorder (letter). July, 300-301
Tricyclics: Possible treatment for posttraumatic stress disorder. Sept, 385-388
Premenstrual Syndrome
Hyperphagia in premenstrual tension syndrome. Oct, 436-438
Pseudocholinesterase and trait anxiety in premenstrual tension syndrome. April, 139-140
Private Hospitals
Electroconvulsive therapy: A survey of use in the private psychiatric hospital. April, 125-127
Propafenone
A case of mania secondary to propafenone. March, 104-105
Psychosis
A case of Capgras delusion presenting as a postpartum psychosis. June, 242-243
Acute organic psychosis caused by thyrotoxicosis and vitamin B12 deficiency: Case report. March, 106-107
Lithium carbonate and the "cycloid spectrum" (letter). Nov, 504-505
Postpartum psychosis as a discrete entity. May, 182-184
Reserpine and phencyclidine-associated psychosis: Three case reports. Dec, 542-544
Psychosocial Therapy
Patterns of attrition for psychosocial and pharmacologic treatments of depression. Sept, 361-366
Psychotherapy
Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: Case report. May, 191-193
Public Policy
Gresham's law in psychiatric illness (editorial). Aug, 308
Race
Race, violence, and psychopathology (letter with reply). Sept, 407
Ranitidine
Partial resolution of ranitidine-associated delirium with physostigmine: Case report. Sept, 400-401
Rapid Tranquilization
Rapid tranquilization: The efficacy of oral concentrate. Nov, 475-478
Rating Scales
Limitations of self-rating depression scales (letter). July, 301
Revised ischemic score for diagnosing multi-infarct dementia. Dec, 514-517
Renal Failure
Non-lithium-induced renal failure with secondary lithium toxicity: Case reports. Jan, 26-28
Reserpine
Reserpine and phencyclidine-associated psychosis: Three case reports. Dec, 542-544
Respiratory Dyskinesia
Respiratory dyskinesia: Review and case reports. June, 232-234
Restraints
The use of restraints on a general psychiatric unit. May, 175-178
Rhabdomyolysis
Psychiatric patients at high risk for rhabdomyolysis (letter with reply). Sept, 406
Salt
Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. Jan, 16-19
Schizophrenia
A long-term follow-up of schizophrenic patients: 1946-1983. June, 210-216
Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: Clinical and animal studies. April, Sec 2, 29-33
Clinical significance, evaluation, and management of secondary depression in schizophrenia. Nov, Sec 2, 26-32

Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Aug, Sec 2, 15-19
Depressive symptoms in acute schizophrenic hospitalized patients. Nov, 483-484
Diagnosis of secondary depression in schizophrenia. Nov, Sec 2, 4-8
Elimination half-life and bioavailability of haloperidol in schizophrenic patients. Jan, 20-21
Frequency and differential diagnosis of depressive syndromes in schizophrenia. Nov, Sec 2, 9-13
Introduction: Secondary depression in schizophrenia. Nov, Sec 2, 3
Is cholecystokinin therapeutic in chronic schizophrenia? Nov, 485-486
Lithium-responsive schizophrenia: Case report. April, 141-142
Maintenance therapy and the natural course of schizophrenia. Nov, Sec 2, 18-21
Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. Jan, 16-19
Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: Case report. May, 191-193
Prodromal symptoms and prevention of relapse in schizophrenia. Nov, Sec 2, 22-25
Recent psychostimulant use in hospitalized schizophrenics. March, 79-83
Similar distribution of schizophrenia and multiple sclerosis (letter). Feb, 73
Suicide in schizophrenia: The Iowa record linkage study. Nov, Sec 2, 14-17

Sedative Hypnotics
Agitation observed during treatment with newer hypnotic drugs. July, 280-283
Is the term "posthypnotic state" misleading? (letter). May, 199
Sleeping pills for the elderly: Are they ever justified? Feb, Sec 2, 9-12

Seizures
Panic attacks and temporal lobe seizures associated with a right temporal lobe arteriovenous malformation: Case report. April, 143-145
Rapid improvement of delusional depression following drug-induced seizures: Case report. April, 146-147

Sex Differences
Plasma levels of amitriptyline: Effect of age and sex. July, 276-277

Sexual Disorders/Deviance
Pathologic masturbation with drastic consequences: Case report. Dec, 537-539

Side Effects: See also Cardiotoxicity; specific drugs
Agranulocytosis in the course of phenothiazine therapy: Case reports. Aug, 341-343
Amoxapine overdose (letter). Dec, 545
Androgen-induced hypomania (letter). Aug, 354-355
Downbeat nystagmus as a side effect of lithium carbonate: Case report. July, 292-293
Erythema multiforme associated with trazodone therapy: Case report. July, 294-295
Lack of amnestic effects of clorazepate on geriatric recall. Dec, 518-520
Lithium-induced neurotoxicity and irreversible brain damage: A possible mechanism and antidote (letter). July, 300
Lithium neurotoxicity in patients with degenerative brain disease (letter with reply). Aug, 354
Metrizamide myelography risk factors: A pseudopsychiatric case presentation. Oct, 439-440
Screening for cognitive toxicity of anticholinergic drugs. Aug, 323-326
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine, Oct, 428-429
The elicitation of a movement disorder by trazodone: Case report. Dec, 535-536
The side effect profile and safety of fluoxetine. March, Sec 2, 59-67
Tonic-clonic seizures with maprotiline (letter). Nov, 503
Treatment-emergent incontinence with lithium. Oct, 444-445

Sleep Disorders: See also Narcolepsy
Definition of sleep apnea (letter). May, 199
Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
Sleep apnea in Alzheimer's dementia: Correlation with mental deterioration. July, 257-261
Treatment of pavor nocturnus with alprazolam (letter). Nov, 504

Social Services
Disability and welfare—Who wants it? July, 273-275

Stimulants
Recent psychostimulant use in hospitalized schizophrenics. March, 79-83

Suicide
Depression and suicidality in eating disorders. April, 118-124
Double suicides (letter with reply). Oct, 453
Family history of suicide in affective disorder patients. Aug, 317-319
Suicide attempt by insulin overdose (letter). Jan, 34
Suicide in schizophrenia: The Iowa record linkage study. Nov, Sec 2, 14-17
Suicide pacts: International comparisons. Jan, 11-15

Tardive Dyskinesia
A therapeutic approach to tardive dyskinesia. April, Sec 2, 19-24
Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: Clinical and animal studies. April, Sec 2, 29-33
Clinical and epidemiologic aspects of tardive dyskinesia. April, Sec 2, 8-13
Experimental tardive dyskinesia. April, Sec 2, 48-50
Molindone and haloperidol in tardive dyskinesia. Aug, Sec 2, 4-7
Observations in tardive dyskinesia (letter). Feb, 73
Prevention and management of tardive dyskinesia. April, Sec 2, 14-18
Recognition and diagnosis of tardive dyskinesia. April, Sec 2, 3-7
Spontaneous and tardive dyskinesias: Clinical and laboratory studies. April, Sec 2, 42-47
Tardive dyskinesia in thiothixene treatment (letter). April, 151
Tardive dyskinesia, impaired recall, and informed consent. Oct, 434-435
The pathophysiology of tardive dyskinesia. April, Sec 2, 38-41
The prevalence of tardive dyskinesia in geropsychiatric outpatienis. Feb, 55-57
Tiapride in the treatment of tardive dyskinesia: A clinical and biochemical study. June, 229-231
Vulnerability to tardive dyskinesia. Sept, 367-368

Theophylline
Theophylline-lithium interaction. July, 278-279

Thiothixene
Tardive dyskinesia in thiothixene treatment (letter). April, 151

Thought Disorder
Geographic category confusion: A sign of thinking disorder (letter). April, 150-151

Thrombocytopenia
Carbamazepine and idiopathic thrombocytopenia (letter). May, 199

Thyroid Disorders
Acute organic psychosis caused by thyrotoxicosis and vitamin B12 deficiency: Case report. March, 106-107
Euthyroid hyperthyroxinemia and rapid cycling in affective disorders: Case report. Feb, 61-63
Use of ECT in a depressed hypothyroid patient. Feb, 64-66

Thyroid Hormones
Thyroid indices in panic disorder. Oct, 432-433
Thyroxine binding and TSH in recurrent depressive episodes. July, 267-272

Tiapride
Tiapride in the treatment of tardive dyskinesia: A clinical and biochemical study. June, 229-231

Tourette's Syndrome
The use of imipramine in Tourette's syndrome and attention deficit disorder: Case report. Aug, 348-349

Toxicity
Brain glycine levels following lithium toxicity: Case report. June, 239

Tranylcypromine
Depression in Binswanger's encephalopathy responsive to tranylcypromine: Case report. Feb, 69-70

Trazodone
Erythema multiforme associated with trazodone therapy: Case report. July, 294-295
The elicitation of a movement disorder by trazodone: Case report. Dec, 535-536

Tricyclic Antidepressants: See also Antidepressants; specific drugs
Acute response to methylphenidate as a predictor of outcome of treatment with TCAs in the elderly. Nov, 466-469
Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: Case report. Nov, 487-488
Combination drug therapy in depression (editorial). June, 205
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. June, 206-209
Tricyclic antidepressant blood levels. Dec, 545
Tricyclic-resistant depression: Treatment resistance or inadequate treatment? Oct, 412-417
Tricyclics: Possible treatment for posttraumatic stress disorder. Sept, 385-388

Trimipramine
A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. March, 90-94
Trimipramine and maprotiline: Antidepressant, anxiolytic, and cardiotoxic comparison. May, 166-171
Trimipramine in physical illness with depression. Feb, Sec 2, 4-8

Turner's Syndrome
Concurrence of Turner's syndrome, anorexia nervosa, and mood disorders: Case report. July, 296-297

Violence
Race, violence, and psychopathology (letter with reply). Sept, 407

Water Intoxication
Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. Jan, 16-19
Water intoxication associated with nephrogenic diabetes insipidus secondary to lithium: Case report. Sept, 402-403

Journal of Clinical Psychiatry

Author Index to Volume 46: January 1985 Through December 1985

Ackerman BJ: Review of Behrman M: *Handbook of Microcomputers in Special Education.* June, 250
Ackerman DL see Greist JH
Adams GL see Chacko RC
Addario D: Developmental considerations in the concept of affective illness. Oct, Sec 2, 46-53
Akiskal HS: A proposed clinical approach to chronic and "resistant" depressions: Evaluation and treatment, Oct, Sec 2, 32-36. Reviews of Beck AT et al: *Anxiety Disorders and Phobias—A Cognitive Perspective,* Oct, 451; Goodwin DW et al: *Psychiatric Diagnosis, Third Edition,* Feb, 71; Goodwin DW: *Phobia—The Facts,* April, 148-149; Pasnau RO (ed): *Diagnosis and Treatment of Anxiety Disorders,* Nov, 500; Sheehan DV: *The Anxiety Disease,* April, 148-149
Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM: Borderline: An adjective in search of a noun. Feb, 41-48
Alarcon RD, Shirriff JR, Kern EE: Euthyroid hyperthyroxinemia and rapid cycling affective disorder: Case report. Feb, 61-63
Albrecht E see Levy SD
Aldrich TE see Fishbain DA
Alvarez WA see Freinhar JP
Ambrosini P see Greenhill LL
Amsterdam JB see Rickels K
Anton AH see Mulgaokar GD
Arana GW see Baldessarini RJ
Arato M see Perenyi A
Aronoff GR see Lemberger L
Assalian P, Rosengarten MD, Phillips R: A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. March, 90-94
Atwood S: Review of Shores MF (ed): *Red is the Color of Hurting.* Aug, 353
Aziz N see Gracia F
Bagdy G see Perenyi A
Baker RW see Zipursky RB
Baldessarini RJ: Clinical and epidemiologic aspects of tardive dyskinesia. April, Sec 2, 8-13
Baldessarini RJ, Arana GW: Does the dexamethasone suppression test have clinical utility in psychiatry? Feb, Sec 2, 25-29
Banay-Schwartz M see Stanley M
Barr GA see Katz IR
Battle AO: Review of DeCato CM et al (eds): *Rorschach Scoring: A Workbook for the Perceptanalytic System.* March, 109
Baudhuin MG see Greist JH
Beck AT: Review of Whybrow PC et al: *Mood Disorders: Toward a New Psychobiology.* Aug, 352
Becker RE: Introduction: Secondary depression in schizophrenia. Nov, Sec 2, 3
Becker RE, Colliver JA, Verhulst SJ: Diagnosis of secondary depression in schizophrenia. Nov, Sec 2, 4-8
Becker RE, Singh MM, Meisler N, Shillicutt S: Clinical significance, evaluation, and management of secondary depression in schizophrenia. Nov, Sec 2, 26-32
Beliack AS see Last CG
Bemporad J: Review of Emde RN, Harmon RJ (eds): *Continuities and Discontinuities in Development.* Sept, 404
Benarroche CL see Glazer WM
Berchou RC see Pomara N
Bergstrom RF see Lemberger L
Berlant JL: Reserpine and phencyclidine-associated psychosis: Three case reports. Dec, 542-544
Berlin RM, Donovan GR, Guerette RC: Funeral mania and lithium prophylaxis (letter). March, 111
Biever J see Cadieux RJ
Bigelow LB see Kirch DG
Biggs JT see Rubin EH
Bitar AH: Review of Hanke N: *Handbook of Emergency Psychiatry.* Sept, 405
Black DW, Cadoret RJ: Reply to Farber IJ: Anorexia nervosa in a 45-year-old man (letter). Aug, 355
Black DW, Wilcox JO, Stewart M: The use of ECT in children: Case report. March, 98-99
Black DW, Winokur G, Warrack G: Suicide in schizophrenia: The Iowa record linkage study. Nov, Sec 2, 14-17
Black JL, Richardson JW: Disulfiram hepatotoxicity: Case report. Feb, 67-68
Blair R, Lippmann S: Metrizamide myelography risk factors: A pseudopsychiatric case presentation. Oct, 439-440
Block R see Pomara N
Blumhardt C see Kellner C
Bolinger JM see Akiskal HS
Borison RL: Pharmacology of antipsychotic drugs. April, Sec 2, 25-28
Bornstein PE: The use of restraints on a general psychiatric unit. May, 175-178
Borod JC see Kermani EJ
Boyer W: The DST: A specialized but important clinical tool (letter). June, 251
Boza RA, Rotondo DJ: Is cholecystokinin therapeutic in chronic schizophrenia? Nov, 485-486
Brenner R, Lesser M: Tear lithium concentration (letter with reply). April, 150
Breslow RE see Demuth GW
Brotman AW see Stern TA
Broverman DM see Vogel W
Brown D see Scharf MB
Brown L see Scharf MB
Brown PH see Kermani EJ
Buckley P see Katz IR
Bueno LF: Review of Hilgard JR, LeBaron S: *Hypnotherapy of Pain in Children with Cancer.* June, 249
Burch M see Mehta D
Burd L see Kerbeshian J
Burstein A: Methylphenidate in diagnosing conversion symptoms (letter), March, 110-111; Panic disorder and PTSD (letter), Oct, 454; Posttraumatic flashbacks, dream disturbances, and mental imagery, Sept, 374-378; Posttraumatic stress disorder (letter), July, 300-301
Bursten B: Reviews of Weckowicz TE: *Models of Mental Illness: Systems and Theories of Abnormal Psychology,* March, 109; Scrignar CB: *Post-Traumatic Stress Disorder: Diagnosis, Treatment, and Legal Issues,* Jan, 31
Cadieux RJ, Kales JD, Kales A, Biever J, Mann LD: Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: Case report. May, 191-193
Cadoret RJ see Black DW
Calloway RA see Cook BL
Cameron OG, Thyer BA: Treatment of pavor nocturnus with alprazolam (letter). Nov, 504
Cantwell DP: Review of Kales A, Kales JD: *Evaluation and Treatment of Insomnia.* Jan, 31-32
Carlson G: Review of Chess S, Thomas A: *Origins and Evolution of Behavior Disorders from Infancy to Early Adult Life.* Nov, 500-501
Carr DB see Fishman SM; Sheehan DV
Carroll BJ: Dexamethasone suppression test: A review of contemporary confusion. Feb, Sec 2, 13-24
Carroll JA see Greist JH
Carvey P see Klawans HL
Case GW see Rickels K
Casey DE: Spontaneous and tardive dyskinesias: Clinical and laboratory studies. April, Sec 2, 42-47
Castellani S: Catatonia associated with phenylpropanolamine overdose and fluphenazine treatment: Case report. July, 288-289
Cavanaugh JJ see Finlayson RE
Chacko RC, Root L, Marmion J, Molinari V, Adams GL: The prevalence of tardive dyskinesia in geropsychiatric outpatients. Feb, 55-57
Chamberlain K see Falcon S
Chang H see Pecknold JC
Charney DS see Goodman WK; Rubin AL
Chen SE see Akiskal HS
Chernow B see Ragan PW
Chiang E, Pitts WM, Rodriguez-Garcia M: Respiratory dyskinesia: Review and case reports. June, 232-234
Chouinard G: A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. March, Sec 2, 32-37. See also **Goldbloom D**
Chung H see Rickels K
Claghorn JL: Review of clinical and laboratory experiences with molindone hydrochloride. Aug, Sec 2, 30-33
Clayton PJ see Martin RL
Cloninger CR see Martin RL
Coffey CE, Ross DR: Lithium neurotoxicity in patients with degenerative brain disease (letter with reply). Aug, 354
Cohen SB: Is the term "posthypnotic state" misleading? (letter). May, 199
Cohn JB, Wilcox C: A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. March, Sec 2, 26-31. See also **Feighner JP**
Coleman JH see Handorf CR; Nasdahl CS
Colliver JA see Becker RE

Cook BL, Smith RE, Perry PJ, Calloway RA: Theophylline-lithium interaction. July, 278-279
Cooper AJ: Review of Bassuk EL, Birk AW (eds): *Emergency Psychiatry—Concepts, Methods, and Practices.* July, 298
Corgiat MD see Templer DI
Csanalosi I see Rickels K
Curtis G see Falcon S
Dalton M see Wright G
Damlouji N see Feighner JP
Dauchot PJ see Mulgaokar GD
Dave MJ: Antipsychotic or neuroleptic? (letter). Oct, 454-455
David JJ see Vieweg WVR
Davis DL see Peterson GA
Davis GC see Akiskal HS; Mellman TA
Davis JM: Maintenance therapy and the natural course of schizophrenia. Nov, Sec 2, 18-21
de la Fuente JR see Salin-Pascual R
De Leo D, Galligioni S, Magni G: A case of Capgras delusion presenting as a postpartum psychosis. June, 242-243
De Soto MF, Griffith SR, Katz EJ: Water intoxication associated with nephrogenic diabetes insipidus secondary to lithium: Case report. Sept, 402-403
DeCastro RM: Antidepressants and myoclonus: Case report. July, 284-287
Delahunt JW see Kathol RG
Demuth GW, Breslow RE, Drescher J: The elicitation of a movement disorder by trazodone: Case report. Dec, 535-536
Deutsch SI see Stanley M
Devanand DP, Nelson JC: Concurrent depression and dementia: Implications for diagnosis and treatment. Sept, 389-392
Devane CL see Dommisse CS
DeWolfe AS see Wolf ME
Diamond R: Drugs and the quality of life: The patient's point of view. May, Sec 2, 29-35
Dillon DC, Salzman LJ, Schulsinger DA: The use of imipramine in Tourette's syndrome and attention deficit disorder: Case report. Aug, 348-349
Djenderedjian A see Welsh SK
Domangue BB, Margolis CG, Lieberman D, Kaji H: Biochemical correlates of hypnoanalgesia in arthritic pain patients. June, 235-238
Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM: A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. March, 84-87
Dommisse CS, Devane CL, Hayes PE: Effect of estrogens on the DST (letter). Nov, 505
Donovan GR see Berlin RM
Downing RW see Rickels K
Drescher J see Demuth GW
Drooby AS: Review of Bellack AS, Hersen M (eds): *Dictionary of Behavior Therapy Techniques.* Oct, 452
Druff JH see Nasdahl CS
Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C: Rapid tranquilization: The efficacy of oral concentrate. Nov, 475-478
Dubovsky SL, Gay M, Franks RD, Haddenhorst A: ECT in the presence of increased intracranial pressure and respiratory failure: Case report. Nov, 489-491
Duffy JP see Mulgaokar GD
Dysken MW, Janowsky DS: Dose-related physostigmine-induced ventricular arrhythmia: Case report. Oct, 446-447
Eaton J see Mehta D
Eliazo CE see Stanley M
Elie R see Pecknold JC
Elliott RL: Alprazolam in severe depression (letter). Jan, 34
Enns GG see Lemberger L
Endicott N see Rifkin A
Erdman HP see Greist JH
Escobar JI, Mann JJ, Keller J, Wilkins J, Mason B, Mills MJ: Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Aug, Sec 2, 15-19
Ewald H see Lassen E
Fabre LF: Treatment of depression in outpatients: A controlled comparison of the onset of action of amoxapine and maprotiline. Dec, 521-524
Fahn S: A therapeutic approach to tardive dyskinesia. April, Sec 2, 19-24
Falcon S, Ryan C, Chamberlain K, Curtis G: Tricyclics: Possible treatment for posttraumatic stress disorder. Sept, 385-388
Familamiri P see Pecknold JC
Farber IJ: Anorexia nervosa in a 45-year-old man (letter with reply). Aug, 355
Farid NA see Lemberger L
Fava GA, Lisansky J, Kellner R, Zielezny M: Treatment responses in primary and secondary melancholia: A preliminary report. Aug, 332-334
Fawcett J, Kravitz H: The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. Feb, 58-60
Feighner JP: A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. Sept, 369-372
Feighner JP, Cohn JB: Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. March, Sec 2, 20-25
Feighner JP, Herbstein J, Damlouji N: Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. June, 206-209
Fernandez-Guardiola A see Salin-Pascual R
Ferrell RB see McAllister TW
Fine EW see Mendels J
Finkel JA see Nurnberg HG
Finlayson RE, Cavanaugh JJ: Reply to Lazarus A: Psychiatric patients at high risk for rhabdomyolysis (letter). Sept, 406
Fisch C: Effect of fluoxetine on the electrocardiogram. March, Sec 2, 42-44
Fishbain DA: Double suicides (letter with reply). Oct, 453
Fishbain DA, Aldrich TE: Suicide pacts: International comparisons. Jan, 11-15
Fishman SM see Sheehan DV
Fishman SM, Sheehan DV, Carr DB: Thyroid indices in panic disorder. Oct, 432-433
Flugelman MY, Tal A, Pollack S, Hefez A, Weisstub EB, Gotsman MS, Lewis BS: Psychotropic drugs and long QT syndromes: Case reports. July, 290-291
Fogel BS, Satel SL: Age, medical illness, and the DST in depressed general hospital inpatients. March, 95-97
Ford HE, Jenike MA: Erythema multiforme associated with trazodone therapy: Case report. July, 294-295
Forster C see Ungerstedt U
Fowler RC see Young D
Franks RD see Dubovsky SL
Frecska E see Perenyi A
Freinhar JP, Alvarez WA: Androgen-induced hypomania (letter), Aug, 354-355; Use of clonazepam in two cases of acute mania. Jan, 29-30
Fristad MA see Weller EE
Fuller RW see Stark P
Gaffney GR, Tune LE: Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine. Oct, 428-429
Galligioni S see De Leo D
Galloway L see Wright G
Ganguli R, Raghu U: Tardive dyskinesia, impaired recall, and informed consent. Oct, 434-435
Garbarino C see Katz IR
Garber HJ see Goff DC
Garrett MD: Use of ECT in a depressed hypothyroid patient. Feb, 64-66
Garvey MJ see Tollefson G
Gay M see Dubovsky SL
Gershon S see McIntyre IM; Pomara N
Giannini AJ, Loiselle RH, Price WA, Giannini MC: Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. Feb, 52-54
Giannini AJ, Price WA, Loiselle RH, Giannini MC: Hyperphagia in premenstrual tension syndrome, Oct, 436-438; Pseudocholinesterase and trait anxiety in premenstrual tension syndrome. April, 139-140
Giannini MC see Giannini AJ
Gibbons R see Janicak PG
Gillman MA, Sandyk R: Maprotiline in nocturnal enuresis (letter). Dec, 546
Gingrich RL Jr see Rickels K
Giandin V see Rickels K
Glazer WM, Hafez HM, Benarroche CL: Molindone and haloperidol in tardive dyskinesia. Aug, Sec 2, 4-7
Goetz CG see Klawans HL
Goff DC, Garber HJ, Jenike MA: Partial resolution of ranitidine-associated delirium with physostigmine: Case report. Sept, 400-401
Gold DD Jr: Reviews of Dubin WR, Hanke N, Nickens HW (eds): *Psychiatric Emergencies,* Jan, 32-33; Tupin et al (eds): *Transient Psychosis: Diagnosis, Management and Evaluation,* May, 198
Goldbloom D, Chouinard G: Schizophreniform psychosis associated with chronic industrial toluene exposure: Case report. Aug, 350-351
Goldstein BJ: Introduction: Theoretical and clinical considerations affecting the selection of neuroleptic agents. Aug, Sec 2, 3. See also **Dominguez RA**
Goldstein JA: Calcium channel blockers in the treatment of panic disorder (letter), Dec, 546. Lithium treatment of central pain (letter). Oct, 453-454
Gonzalez JR: Panic anxiety (letter). Oct, 455
Goodman WK, Charney DS: Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs. Oct, Sec 2, 6-22
Goodwin DW see Mac DS
Gotsman MS see Flugelman MY
Gracia F, Koch J, Aziz N: Downbeat nystagmus as a side effect of lithium carbonate: Case report. July, 292-293
Greenberg WH see Katz IR
Greenblatt DJ see Pomara N
Greenhill LL, Solomon M, Pleak R, Ambrosini P: Molindone hydrochloride treatment of hospitalized children with conduct disorder. Aug, Sec 2, 20-25
Greist JH: Review of Dubovsky SL et al (eds): *Psychiatric Decision Making.* Aug, 352-353
Greist JH, Jefferson JW, Ackerman DL, Baudhuin MG, Erdman HP, Carroll JA: Lithium Information Center: The Lithium Library revisited. Aug, 327-331
Griffith SR see De Soto MF
Grumet GW: Pathologic masturbation with drastic consequences: Case report. Dec, 537-539
Grunberger J see Saletu B
Guerette RC see Berlin RM
Gultekin A see Lippmann SB
Gunne LM, Haggstrom JE: Experimental tardive dyskinesia. April, Sec 2, 48-50
Gunter MJ: Definition of sleep apnea (letter). May, 199
Guze SB see Martin RL
Hackstaff L see Rifkin A
Haddenhorst A see Dubovsky SL
Hafez HM see Glazer WM
Haggstrom JE see Gunne LM
Handorf CR: Tricyclic antidepressant blood levels (letter). Dec, 545
Handorf CR, Coleman JH, Rawls WN: Elevated serum bromide in patients taking lithium carbonate. Jan, 9-10
Hannah L see Kathol RG
Hardison CD see Stark P
Harris P see Kellner C
Hayes PE see Dommisse CS
Hefez A see Flugelman MY
Heninger GR see Rubin AL
Herbstein J see Feighner JP
Herrera-Marschitz M see Ungerstedt U
Hersen M see Last CG
Herz M: Prodromal symptoms and prevention of relapse in schizophrenia. Nov, Sec 2, 22-25
Himmelhoch JM see Last CG
Hirschowitz J see Scharf MB
Hoch CC see Reynolds CF
Hoffmann N see Tollefson G
Hollister LE see Magliozzi JR
Hudson JI, Wentworth SM, Hudson MS, Pope HG: Prevalence of anorexia nervosa and bulimia among young diabetic women. March, 88-89
Hudson MS see Hudson JI
Jack RA: A case of mania secondary to propafenone. March, 104-105
Jacobson AF see Dominguez RA
Jaffe JH see Khan A
Janicak PG, Mask J, Trimakas KA, Gibbons R: ECT: An assessment of mental health professionals' knowledge and attitudes. July, 262-266

Janowsky DS see Dysken MW; Zisook S
Jatlow PI see McCormick SR
Jefferson JW: Reply to Brenner R, Lesser M: Tear lithium concentration (letter), April, 150. See also **Greist JM**
Jenike MA see Ford HE; Goff DC
Jeste DV, Wyatt RJ: Prevention and management of tardive dyskinesia. April, Sec 2, 14-18
Johnson DAW: Antipsychotic medication: Clinical guidelines for maintenance therapy. May, Sec 2, 6-15
Johnston JA see Nasdahl CS
Kaji H see Domangue BB
Kales A see Cadieux RJ
Kales JD see Cadieux RJ
Kane JM: Antipsychotic drug side effects: Their relationship to dose. May, Sec 2, 16-21
Karagji B see Rifkin A
Kashani JH: Review of Ricks DF, Dohrenwend BS (eds): *Origins of Psychopathology: Problems in Research and Public Policy.* Sept, 404
Kashgarian M see Akiskal HS
Kathol RG, Delahunt JW, Hannah L: Transition from bipolar affective disorder to intermittent Cushing's syndrome: Case report. May, 194-196
Katz EJ see De Soto MF
Katz IR, Greenberg WH, Barr GA, Garbarino C, Buckley P, Smith D: Screening for cognitive toxicity of anticholinergic drugs. Aug, 323-326
Kaufman MW see Kondziela JR
Kazamatsuri H, Nanko S, Mato Y: Homicidality in a woman with a 47,XXX karyotype. Aug, 346-347
Keller J see Escobar JI
Kellner C, Harris P, Blumhardt C: Concurrent use of bromocriptine and fluphenazine (letter). Oct, 455
Kellner R see Fava GA
Kelwala S, Pomara N, Stanley M: Reply to Coffey CE, Ross DR: Lithium neurotoxicity in patients with degenerative brain disease (letter). Aug, 354
Kerbeshian J, Burd L: Auditory hallucinosis and atypical tic disorder: Case reports. Sept, 398-399
Kermani EJ, Borod JC, Brown PH, Tunnell G: New psychopathologic findings in AIDS: Case report. June, 240-241
Kern EE see Alarcon RD
Khan A, Jaffe JH, Nelson WH, Morrison B: Resolution of neuroleptic malignant syndrome with dantrolene sodium: Case report. June, 244-246
Kim J see Wright G
Kim YS see Rifkin A
Kirch DG, Bigelow LB, Weinberger DR, Lawson WB, Wyatt RJ: Polydipsia and chronic hyponatremia in schizophrenic inpatients. May, 179-181
Kniber EL see Vogel W
Klawans HL: Recognition and diagnosis of tardive dyskinesia. April, Sec 2, 3-7
Klawans HL, Carvey P, Tanner CM, Goetz CG: The pathophysiology of tardive dyskinesia. April, Sec 2, 38-41
Klein MJ see Kondziela JR
Kline NA, Rausch JL: Olfactory precipitants of flashbacks in posttraumatic stress disorder: Case reports. Sept, 383-384
Koch J see Gracia F
Koch M see Lesar TS
Kolman PBR: Predicting the results of routine laboratory tests in elderly psychiatric patients admitted to hospital. Dec, 532-534
Kondziela JR, Kaufman MW, Klein MJ: Diabetic ketoacidosis associated with lithium: Case report. Nov, 492-493
Kook KA, Stimmel GL, Wilkins JN, Spangher GG: Accuracy and safety of a priori lithium loading. Feb, 49-51
Kranzler H: Tonic-clonic seizures with maprotiline (letter). Nov, 503
Kraus RP, Remick RA: Dexamethasone suppression test results in delusional versus nondelusional depression: Preliminary evidence of distinct clinical entities. May, 188-190
Kravitz H see Fawcett J
Kumar R see Mac DS
Kupfer DJ: Introduction: "Controversies in Psychiatry," Feb, Sec 2, 3. See also **Reynolds CF**
Kuyumjian R: Review of Frances A et al: *Differential Therapeutics in Psychiatry: The Art and Science of Treatment Selection.* Sept, 404-405
Lam RW, Remick RA: Alprazolam-induced manic switch (letter). Sept, 406-407
La Rue A see Spar JA
Larocca FEF: Concurrence of Turner's syndrome, anorexia nervosa, and mood disorders: Case report, July, 296-297. Review of Vandereycken W, Moormann R: *Anorexia Nervosa: A Clinician's Guide to Treatment,* Feb, 71-72
Larson MM see Robbins DR
Lassen E, Ewald H: Acute organic psychosis caused by thyrotoxicosis and vitamin B12 deficiency: Case report. March, 106-107
Last CG, Thase ME, Hersen M, Bellack AS, Himmelhoch JM: Patterns of attrition for psychosocial and pharmacologic treatments of depression. Sept, 361-366
Lawlor BA see Stewart JT
Lawson WB: Reply to Logan PH: Race, violence and psychopathology (letter), Sept, 407. See also **Kirsch DG**
Lazarus A: Psychiatric patients at high risk for rhabdomyolysis (letter with reply). Sept, 406
Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR: Fluoxetine: Clinical pharmacology and physiologic disposition. March, Sec 2, 14-19
Lerer B: Alternative therapies for bipolar disorder. Aug, 309-316
Lerner Y, Moscovich D: Depressive symptoms in acute schizophrenic hospitalized patients. Nov, 483-484
Lesar TS, Tollefson G, Koch M: Relationship between patient variables and lithium dosage requirements. April, 133-136
Lesser M see Brenner R
Levine SB: Review of Steiner BW (ed): *Gender Dysphoria: Development, Research, Management.* Nov, 501-502
Levy SD, Albrecht E: Electroconvulsive therapy: A survey of use in the private psychiatric hospital. April, 125-127
Lewis BS see Flugelman MY
Lieber AL, Newbury N: Use of biologic markers in a general hospital affective disorders program. June, 217-221
Lieberman D see Domangue BB
Lindsay PG, Olsen RB: Maprotiline in pain-depression. June, 225-228
Lippmann S see Blair R
Lippmann SB, Manshadi MS, Gultekin A: Monoamine oxidase inhibitors for depressed cardiac patients (letter). Dec, 545-546
Lips O see Wolf ME
Lisansky J see Fava GA
Liskow BI see Richard ML
Logan PH: Race, violence, and psychopathology (letter with reply). Sept, 407
Loiselle RH see Giannini AJ
Loyd DW, Tsuang MT: Disability and welfare—Who wants it? July, 273-275
Lunsky L: Review of Greenfield D: *The Psychotic Patient. Medication and Psychotherapy.* Oct, 452
Lutz EG: Carbamazepine and idiopathic thrombocytopenia (letter). May, 199
Lydiard RB: Tricyclic-resistant depression: Treatment resistance or inadequate treatment? Oct, 412-417
Mac DS see Preskorn SH
Mac DS, Kumar R, Goodwin DW: Anterograde amnesia with oral lorazepam. April, 137-138
Mackay AVP: New antipsychotic agents and the future. April, Sec 2, 51-53
Magliozzi JR, Hollister LE: Elimination half-life and bioavailability of haloperidol in schizophrenic patients. Jan, 20-21
Magni G see De Leo D
Mallon PM see Yerevanian BI
Mallya G: Review of Salzman C (ed): *Clinical Geriatric Psychopharmacology.* June, 249
Mann JJ see Escobar JI
Mann LD see Cadieux RJ
Manshadi MS see Lippmann SB
Margolis CG see Domangue BB
Marin RS see Reynolds CF
Marmion J see Chacko RC
Martin D see Reynolds CF
Martin RL, Cloninger CR, Guze SB, Clayton PJ: Frequency and differential diagnosis of depressive syndromes in schizophrenia. Nov, Sec 2, 9-13
Mask J see Janicak PG
Mason B see Escobar JI
Mato Y see Kazamatsuri H
Mattes JA: Methylphenidate in mild depression: A double-blind controlled trial. Dec, 525-527
Mavissakalian M: Review of Franks CM (ed): *New Developments in Behavior Therapy: From Research to Clinical Implication.* March, 108
May CN see Nasdahl CS
McAllister TW: Carbamazepine in mixed frontal lobe and psychiatric disorders. Sept, 393-394
McAllister TW, Price TRP, Ferrell RB: Bilateral sinusoidal ECT following poor response to five unilateral brief-pulse ECTs. Oct, 430-431
McClure DJ see Pecknold JC
McCormick SR, Nielsen J, Jatlow PI: Alprazolam overdose: Clinical findings and serum concentrations in two cases. June, 247-248
McIntyre IM, Gershon S: Interpatient variations in antipsychotic therapy. May, Sec 2, 3-5
Mehta D, Eaton J, Burch M, Mehta S: Observations in tardive dyskinesia (letter). Feb, 73
Mehta S see Mehta D
Meisler N see Becker RE
Mellman TA, Davis GC: Combat-related flashbacks in posttraumatic stress disorder: Phenomenology and similarity to panic attacks. Sept, 379-382
Mendels J, Wasserman TW, Michals TJ, Fine EW: Halazepam in the management of acute alcohol withdrawal syndrome. May, 172-174
Michals TJ see Mendels J
Mielke D see Wall M
Miller L see Wright G
Mills MJ see Escobar JI
Mohelsky HE see Yassa R
Molinari V see Chacko RC
Molloy AG see Waddington JL
Montgomery SA: Development of new treatments for depression. March, Sec 2, 3-6
Morrison B see Khan A
Morycz R see Reynolds CF
Moscovich D see Lerner Y
Mosnaim AD see Wolf ME
Mulgaokar GD, Dauchot PJ, Duffy JP, Amon AH: Noninvasive assessment of electroconvulsive-induced changes in cardiac function. Nov, 479-482
Munoz RA: Postpartum psychosis as a discrete entity. May, 182-184
Nadelson CC: Introduction: Update on the clinical management of affective illness. Oct, Sec 2, 3-5
Nanko S see Kazamatsuri H
Nasdahl CS, Johnston JA, Coleman JH, May CN, Druff JH: Protocols for the use of psychoactive drugs—Part IV: Protocol for the treatment of anxiety disorders. April, 128-132
Nelson J see Reynolds CF
Nelson JC see Devanand DP
Nelson WH see Khan A
Newbury N see Lieber AL
Newton RE see Pomara N
Nielsen J see McCormick SR
Novac A: Lithium carbonate and the "cycloid spectrum" (letter). Nov, 504-505
Nurnberg HG, Finkel JA: Carbamazepine in bipolar-depressed disorder complicated by tricyclic antidepressant switching: Case report. Nov, 487-488
O'Boyle KM see Waddington JL
Olsen RB see Lindsay PG
Ostrow D: The new generation antidepressants: Promising innovations or disappointments? Oct, Sec 2, 25-30
Othmer E see Othmer SC; Powell BJ
Othmer SC, Othmer E, Varanka TM, Strong DM: Refractory migraine headache controlled with alprazolam: Case report. Nov, 494-495
Overall JE see Zisook S
Pecknold JC, Familamiri P, McClure DJ, Elie R, Chang H: Trimipramine and maprotiline: Antidepressant, anxiolytic, and cardiotoxic comparison. May, 166-171

Peltier-Saxe D see Sheehan DV
Penick EC see Powell BJ
Peper M: Clinical experience with molindone hydrochloride in geriatric patients. Aug, Sec 2, 26-29
Perenyi A, Arato M, Bagdy G, Frecska E, Szucs R: Tiapride in the treatment of tardive dyskinesia: A clinical and biochemical study. June, 229-231
Perry PJ see Cook BL; Richard ML
Peselow ED see Stanley M
Peterson GA, Davis DL: A case of homosexual erotomania. Oct, 448-449
Phillips R see Assalian P
Pitts FN Jr: Combination drug therapy in depression (editorial), June, 205. Editorial, Sept, 373
Pitts WM see Chiang E
Pleak R see Greenhill LL
Pollack MH see Rosenbaum JF
Pollack S see Flugelman MY
Pomara N see Kelwala S
Pomara N, Stanley B, Block R, Berchou RC, Stanley M, Greenblatt DJ, Newton RE, Gershon S: Increased sensitivity of the elderly to the central depressant effects of diazepam. May, 185-187
Pope HG see Hudson JI
Powell BJ, Penick EC, Othmer E: The discriminate validity of the psychiatric diagnostic interview. Aug, 320-322
Prakash R: Lithium-responsive schizophrenia: Case report. April, 141-142
Preskorn SH see Rubin EH; Weller EE
Preskorn SH, Mac DS: Plasma levels of amitriptyline: Effect of age and sex. July, 276-277
Price LH see Rubin AL
Price TRP see McAllister TW
Price WA see Giannini AJ
Pugh MT see Waddington JL
Puzantian VR see Akiskal HS
Ragan PW, Chernow B, Resnik HLP: Suicide attempt by insulin overdose (letter). Jan, 34
Ragheb M: Drug abuse among state hospital psychiatric inpatients with particular reference to PCP. Aug, 339-340
Raghu U see Ganguli R
Ramchandani D see Dubin WR
Raskin DE: Antipsychotic medication and the elderly. May, Sec 2, 36-40
Rausch JL see Kline NA
Rawls WN see Handorf CR
Reardon G see Rifkin A
Regestein QR, Reich P: Agitation observed during treatment with newer hypnotic drugs. July, 280-283
Regier MW see Templer DI
Reich J, Steward MS, Tupin JP, Rosenblatt RM: Prediction of response to treatment in chronic pain patients. Oct, 425-427
Reich P see Regestein QR
Reid WH: Review of Bursten B: *Beyond Psychiatric Expertise.* Oct, 451
Reiss AL: Developmental manifestations in a boy with prepubertal bipolar disorder. Oct, 441-443
Remick RA see Kraus RP; Lam R
Resnick M: Reply to Wolf JM: Droperidol and haloperidol in the treatment of acute agitation (letter). Sept, 407
Resnik HLP see Ragan PW
Restifo K see Reynolds CF
Reynolds CF, Kupfer DJ, Hoch CC, Sewitch DE: Sleeping pills for the elderly: Are they ever justified? Feb, Sec 2, 9-12
Reynolds CF, Kupfer DJ, Taska LS, Hoch CC, Sewitch DE, Restifo K, Spiker DG, Zimmer B, Marin RS, Nelson J, Martin D, Morcyz R: Sleep apnea in Alzheimer's dementia: Correlation with mental deterioration. July, 257-261
Rice SN: Review of Glenn ML: *On Diagnosis: A Systemic Approach.* March, 108
Rich CL see Young D
Richard ML, Liskow BI, Perry PJ: Recent psychostimulant use in hospitalized schizophrenics. March, 79-83
Richardson JW see Black JL
Richelson E: Pharmacology of neuroleptics in use in the United States. Aug, Sec 2, 8-14
Rickels K, Downing RW, Case GW, Csanalosi I, Chung H, Winokur A, Gingrich RL Jr: Six-week trial with diazepam: Some clinical observations. Nov, 470-474
Rickels K, Smith WT, Glaudin V, Amsterdam JB, Weise C, Settle GP: Comparison of two dosage regimens of fluoxetine in major depression. March, Sec 2, 38-41
Rifkin A, Reardon G, Siris S, Karagji B, Kim YS, Hackstaff L, Endicott N: Trimipramine in physical illness with depression. Feb, Sec 2, 4-8
Rinsley DB: Review of Strean HS (ed): *Psychoanalytic Approaches to the Resistant and Difficult Patient.* July, 299
Risch SC see Zisook S
Robbins DR, Larson MM: Limitations of self-rating depression scales (letter). July, 301
Rodriguez-Garcia M see Chiang E
Roig M see Viesselman JO
Root L see Chacko RC
Rosenbaum JF, Pollack MH: Treatment-emergent incontinence with lithium. Oct, 444-445
Rosenberg DJ see Weiss KJ
Rosenblatt RM see Reich J
Rosengarten MD see Assalian P
Rosenthal RH: Review of Pinkston EM, Linsk NL: *Care of the Elderly: A Family Approach.* May, 197-198
Ross DR see Coffey CE
Rotondo DJ see Roza RA
Rowe WT see Vleweg WVR
Roy A: Family history of suicide in affective disorder patients. Aug, 317-319
Rubin AL, Charney DS, Price LH, Heninger GR: Rapid improvement of delusional depression following drug-induced seizures: Case report. April, 146-147
Rubin EH, Biggs JT, Preskorn SH: Nortriptyline pharmacokinetics and plasma levels: Implications for clinical practice. Oct, 418-424
Ryan C see Falcon S
Ryan JJ see Wolf ME
Saletu B, Grunberger J: Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG, and psychometric analyses. March, Sec 2, 45-52
Salin-Pascual R, de la Fuente JR, Fernandez-Guardiola A: Effects of clonidine in narcolepsy. Dec, 528-531
Salzman C: Clinical guidelines for the use of antidepressant drugs in geriatric patients. Oct, Sec 2, 38-44
Salzman LJ see Dillon DC
Sandifer MG: Ordinary conditions for indefinite continuation of lithium therapy (letter). Nov, 505
Sandyk R see Gillman MA
Saran AS: Depression after minor closed head injury: Role of dexamethasone suppression test and antidepressants. Aug, 335-338
Satel SL see Fogel BS
Scharf MB, Brown D, Woods M, Brown L, Hirschowitz J: The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy. June, 222-225
Scharf MB, Hirschowitz J, Woods M, Scharf S: Lack of amnestic effects of clorazepate on geriatric recall. Dec, 518-520
Scharf S see Scharf MB
Schatzberg AF: Discussion of "Controversies in Psychiatry": Depression in the medically ill, sleep disorders in the elderly, and the DST. Feb, Sec 2, 30-31
Schiffer RB see Yerevanian BI
Schorer CE: Geographic category confusion: A sign of thinking disorder (letter). April, 150-151
Schulsinger DA see Dillon DC
Schuyler D: Review of Hoffman N (ed): *Foundations of Cognitive Therapy: Theoretical and Practical Applications.* May, 197
Scott-Strauss A: Review of Brody CM (ed): *Women Therapists Working With Women: New Theory and Process of Feminist Therapy.* June, 249-250
Settle GP see Rickels K
Sewitch DE see Reynolds CF
Sheehan DV see Fishman SM
Sheehan DV, Carr DB, Fishman SM, Walsh MM, Peltier-Saxe D: Lactate infusion in anxiety research: Its evolution and practice. May, 158-165
Shillicutt S see Becker RE
Shirriff JR see Alarcon RD
Shucter SR: Review of Munoz RA (ed): *Therapeutic Potential of Mood Disorders Clinics.* April, 149
Simonson M: L-phenylalanine (letter). Aug, 355
Simpson GM, Yadalam K: Blood levels of neuroleptics: State of the art. May, Sec 2, 22-28
Singh MM see Becker RE
Siris SG: Three cases of akathisia and "acting out," Sept, 395-397. See also **Rifkin A**
Small GW: Revised ischemic score for diagnosing multi-infarct dementia. Dec, 514-517
Smith D see Katz IR
Smith RE see Cook BL
Smith WT see Rickels K
Solomon M see Greenhill LL
Spangler GG see Kook KA
Spar JA, La Rue A: Acute response to methylphenidate as a predictor of outcome of treatment with TCAs in the elderly. Nov, 466-469
Spector I: AMP: A new form of marijuana. Nov, 498-499
Spiker DG see Reynolds CF
Spradlin WW see Vleweg WVR
St. John R: Review of Myers WA: *Dynamic Therapy of the Older Patient.* Oct, 451-452
Stanley B see Pomara N
Stanley M see Kelwala S; Pomara N
Stanley M, Deutsch SI, Banay-Schwartz M, Peselow ED, Eliazo CE: Brain glycine levels following lithium toxicity: Case report. June, 239
Stark P, Fuller RW, Wong DT: The pharmacologic profile of fluoxetine. March, Sec 2, 7-13
Stark P, Hardison CD: A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. March, Sec 2, 53-58
Steinbook RM see Dominguez RA
Stern TA, Brotman AW: Non-lithium-induced renal failure with secondary lithium toxicity: Case reports. Jan, 26-28
Stern W see Wright G
Steward MS see Reich J
Stewart JT: Carbamazepine treatment of a patient with Kluver-Bucy syndrome. Nov, 496-497
Stewart JT, Lawlor BA: Depression, agoraphobia, and the DST (letter). Nov, 503-504
Stewart M see Black DW
Stimmel GL see Kook KA
Strong DM see Othmer SC
Summergrad P: Depression in Binswanger's encephalopathy responsive to tranylcypromine: Case report. Feb, 69-70
Szucs R see Perenyi A
Tal A see Flugelman MY
Tanner CM see Klawans HL
Taska LS see Reynolds CF
Tavani-Petrone C see Dubin WR
Teare M see Weller EE
Templer DI, Regier MW, Corgiat MD: Similar distribution of schizophrenia and multiple sclerosis (letter). Feb, 73
Thase ME see Last CG
Thyer BA see Cameron OG
Tollefson G see Lesar TS
Tollefson G, Valentine R, Hoffmann N, Garvey MJ, Tuason VB: Thyroxine binding and TSH in recurrent depressive episodes. July, 267-272
Trimakas KA see Janicak PG
Troisno G: Amitriptyline and contact lenses (letter). May, 199
Tsuang MT see Loyd DW
Tuason VB see Tollefson G
Tuchman M see Wall M
Tune LE see Gaffney GR
Tunnell G see Kermani EJ
Tupin JP see Reich J
Ungerstedt U, Herrera-Marschitz M, Forster C: Neuroleptic drugs and their action on different neuronal pathways. April, Sec 2, 34-37
Valdiserri EV: A possible interaction between lithium and diltiazem: Case report. Dec, 540-541
Valentine R see Tollefson G
Varanka TM see Othmer SC
Verhulst SJ see Becker RE

Vlesselman JO, Roig M: Depression and suicidality in eating disorders. April, 118-124

Vieweg WVR, Rowe WT, David JJ, Spradlin WW: Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. Jan, 16-19

Vogel W, Klaiber EL, Broverman DM: A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. Jan, 6-8

Waddington JL, Youssef HA, Molloy AG, O'Boyle KM, Pugh MT: Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: Clinical and animal studies. April, Sec 2, 29-33

Wall M, Tuchman M, Mielke D: Panic attacks and temporal lobe seizures associated with a right temporal lobe arteriovenous malformation: Case report. April, 143-145

Walsh MM see Sheehan DV

Warneke LB: Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: Case report. March, 100-103

Warrack G see Black DW

Wasserman TW see Mendels J

Watts CAH: A long-term follow-up of schizophrenic patients: 1946-1983. June, 210-216

Waxman HM see Dubin WR

Waziri R: Review of Saletu B et al: *Neurophysiological Correlates of Mental Disorders.* Nov, 501

Weaver KEC: Amoxapine overdose (letter). Dec, 545

Weinberger DR see Kirch DG

Weise C see Rickels K

Weiss KJ see Dubin WR

Weiss KJ, Rosenberg DJ: Prevalence of anxiety disorders among alcoholics. Jan, 3-5

Weisstub EB see Flugelman MY

Weller E: Review of Cicchetti D, Schneider-Rosen K (eds): *Childhood Depression: New Directions for Child Development.* Sept, 405

Weller EE, Weller RA, Fristad MA, Preskorn SH, Teare M: The dexamethasone suppression test in prepubertal depressed children. Dec, 511-513

Weller RA see Weller EE

Welsh SK, Djenderedjian A: Review of Walsh M: *Schizophrenia: Straight Talk for Families and Friends.* Aug, 353

Wentworth SM see Hudson JI

Wernicke JF: The side effect profile and safety of fluoxetine. March, Sec 2, 59-67

West AP: Lithium-induced neurotoxicity and irreversible brain damage: A possible mechanism and antidote (letter). July, 300

Widlocher D: Review of Werman DS: *The Practice of Supportive Psychotherapy.* July, 298-299

Wilcox C see Cohn JB

Wilcox JO see Black DW

Wilkins J see Escobar JI

Wilkins JN see Kook KA

Winokur A see Rickels K

Winokur G: Gresham's law in psychiatric illness (editorial). Aug, 308. See also **Black DW**

Wolen RL see Lemberger L

Wolf JM: Droperidol and haloperidol in the treatment of acute agitation (letter with reply). Sept, 407

Wolf ME, DeWolfe AS, Ryan JJ, Lips O, Mosnaim AD: Vulnerability to tardive dyskinesia. Sept, 367-368

Wong DT see Stark P

Woods M see Scharf MB

Wright G, Galloway L, Kim J, Dalton M, Miller L, Stern W: Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects. Jan, 22-25

Wyatt RJ see Jeste DV; Kirch DG

Yadalam K see Simpson GM

Yassa R: Agranulocytosis in the course of phenothiazine therapy: Case reports. Aug, 341-343

Yassa R, Mohelsky HE: Tardive dyskinesia in thiothixene treatment (letter). April, 151

Yerevanian BI, Schiffer RB, Mallon PM: Electroencephalographic abnormalities in borderline patients (letter). June, 251

Young D, Rich CL, Fowler RC: Reply to Fishbain DA: Double suicides (letter). Oct, 453

Youssef HA see Waddington JL

Zielezny M see Fava GA

Zimmer B see Reynolds CF; Zipursky RB

Zimmerman M: The validity of the DST (letter). March, 110

Zipursky RB, Baker RW, Zimmer B: Alprazolam withdrawal delirium unresponsive to diazepam: Case report. Aug, 344-345

Zisook S, Janowsky DS, Overall JE, Risch SC: The dexamethasone suppression test and unipolar/bipolar distinctions. Nov, 461-465